相关实验视频
Updated: Sep 16, 2025

05:42
The Forced Swim Test as a Model of Depressive-like Behavior
Published on: March 2, 2015
37.8K
当情绪和时间对齐时:鼻腔埃斯基他明可以减少治疗耐药抑郁症患者的经历时间障碍
Stefan Jerotic1,2, Milica Nestorovic2, Janko Nesic3
1Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
International journal of psychiatry in clinical practice
|July 10, 2025
概括
鼻腔埃斯基坦胺在治疗耐药性抑郁症方面表现有前途. 评估主观时间感知 (TATE) 的结构化面试检测到传统尺度 (MADRS) 之前的改善,突出了其在测量治疗有效性的实用性.
科学领域:
- 精神病学是一个精神病学.
- 临床心理学 临床心理学
- 神经科学是一个神经科学.
背景情况:
- 耐治疗抑郁症 (TRD) 是一个重大的临床挑战.
- 传统的抑郁症尺度可能无法完全捕捉主观改善.
- 评估主观经验对于全面的治疗评估至关重要.
研究的目的:
- 评估结构化现象学面试的有用性,即时间经验的跨诊断评估 (TATE),用于测量抑郁症治疗的有效性.
- 为了将TATE对变化的敏感性与标准抑郁症量表,蒙哥马利-阿斯伯格抑郁症评级量表 (MADRS) 进行比较.
主要方法:
- 两名患有治疗耐药性抑郁症的男性患者接受了鼻腔以斯基坦胺.
- 使用MADRS和TATE监测临床进展.
- TATE评估患者的主观时间感,这是现象学经验的关键方面.
主要成果:
- 在一例中,TATE得分在第4周正常化至一般人群水平.
- 这种正常化发生在MADRS.表明的治疗反应前一周.
- 这表明TATE可能为治疗疗效提供更早的见解.
结论:
- 像TATE这样的结构化现象学面试可以成为评估抑郁症治疗有效性的宝贵工具.
- 通过捕捉主观体验的微妙改进,TATE补充了传统的尺度.
- 现象学评估为TRD的治疗反应提供了独特的视角.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
373
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
373
Electroconvulsive Therapy
200
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
200
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
609
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
609
Sedatives and Hypnotics Drugs: Miscellaneous Agents
247
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
247
Antiepileptic Drugs: Potassium Channel Activators
283
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
283
Drugs Affecting Neurotransmitter Release or Uptake
1.2K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.2K

